Immatics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Immatics şirketinin toplam hissedar öz sermayesi €382.5M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €577.2M ve €194.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€490.52m
Eşitlik	€382.53m
Toplam yükümlülükler	€194.71m
Toplam varlıklar	€577.23m

Son finansal sağlık güncellemeleri

Recent updates

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Sep 21

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Jul 12

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

May 03

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Sep 26

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Jun 12

Immatics launches $110M stock offering

Oct 10

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Jul 19

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Jan 29

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Dec 16

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18

Immatics reports Q3 results

Dec 02

Immatics (IMTX) Investor Presentation - Slideshow

Nov 13

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IMTX 'nin kısa vadeli varlıkları ( €512.8M ) kısa vadeli yükümlülüklerini ( €128.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: IMTX şirketinin kısa vadeli varlıkları ( €512.8M ) uzun vadeli yükümlülüklerini ( €65.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IMTX borçsuzdur.

Borcun Azaltılması: IMTX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IMTX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: IMTX serbest nakit akışı her yıl % 14.6 2.8 yıl yetecek nakit akışına sahip olacaktır.

Immatics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Recent updates

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $150.3125 million.

Immatics N.V. has filed a Follow-on Equity Offering.

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.9% to US$17.50

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 10%

New major risk - Revenue and earnings growth

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Price target increased by 8.2% to US$19.83

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 42%

Investor sentiment improves as stock rises 22%

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$18.25

Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021)

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 76%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame

Immatics launches $110M stock offering

Investor sentiment deteriorated over the past week

Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022

Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Price target decreased to US$20.00

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Price target decreased to US$22.80

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Consensus forecasts updated

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Consensus forecasts updated

Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.38 loss per share (vs €18.08 loss in 2Q 2020)

Supervisory Director Christof Hettich has left the company

Supervisory Director Christof Hettich has left the company

Consensus forecasts updated

First quarter 2021 earnings released: €0.34 loss per share (vs €7.14 loss in 1Q 2020)

Immatics Presents Preclinical Proof-Of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Full year 2020 earnings released: €4.77 loss per share (vs €0.95 loss in FY 2019)

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Immatics N.V., Annual General Meeting, Jun 17, 2021

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

New 90-day high: US$11.56

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?